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a  b  s  t  r  a  c  t
Although  an association  between  both  sleep  duration  and  disturbance  with  salivary  cortisol  has  been
suggested,  little  is  known  about  the  long  term effects  of  poor  quality  sleep  on  diurnal  cortisol  rhythm.
The  aim  of this  study  was  to  examine  the  association  of poor  quality  sleep,  categorised  as  recurrent  short
sleep  duration  and chronic  insomnia  symptoms,  with the diurnal  release  of  cortisol.  We  examined  this  in
3314  participants  from  an occupational  cohort,  originally  recruited  in  1985–1989.  Salivary  cortisol  was
measured  in  2007–2009  and  six  saliva  samples  were  collected:  (1)  waking,  (2) waking  + 0.5  h, (3) +2.5  h,
(4)  +8  h,  (5)  +12  h and  (6)  bedtime,  for  assessment  of  the  cortisol  awakening  response  and  the  diurnal
slope  in  cortisol  secretion.  Participants  with  the  ﬁrst  saliva  sample  collected  within  15 min of  waking  and
not  on  steroid  medication  were  examined.  Short  sleep  duration  (≤5 h)  and  insomnia  symptoms  (Jenkins
scale,  highest  quartile)  were  measured  in  1997–1999,  2003–2004  and  2007–2009.  Recurrent  short  sleep
was  associated  with  a ﬂatter  diurnal  cortisol  pattern.  A steeper  morning  rise in cortisol  was observed
among  those  reporting  chronic  insomnia  symptoms  at three  time  points  and  among  those  reporting
short  sleep  twice,  compared  to  those  who  never  reported  sleep  problems.  Participants  reporting  short
sleep  on  three  occasions  had  higher  levels  of  cortisol  later  in the  day,  compared  to  those  never  reporting
short  sleep,  indicated  by a positive  interaction  with  hours  since  waking  (ˇ =  0.02 (95%  CI: 0.01,  0.03)).  We
conclude  that  recurrent  sleep  problems  are  associated  with  adverse  salivary  cortisol  patterns  throughout
the day.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Poor quality sleep is associated with a number of chronic
onditions including type 2 diabetes, coronary heart disease,
ypertension (Cappuccio, 2007; Cappuccio et al., 2010; Chandola
t al., 2010; Knutson et al., 2006; Larcher et al., 2015; Shan
t al., 2015) and mortality (Ferrie, 2007; Rod et al., 2014). The
ypothalamic–pituitary–adrenal (HPA) axis has been suggested
s a potential mechanism for this association, since experimental
vidence has found that sleep deprivation is associated with tempo-
ary changes in HPA-related stress markers, such as cortisol (Meerlo
t al., 2008). A recent narrative review evaluated evidence on sleep
nd cortisol (Garde et al., 2012) and concluded that there was  a
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M.J. Shipley), j.ferrie@ucl.ac.uk (J.E. Ferrie), mika.kivimaki@helsinki.ﬁ
M.  Kivimäki), mkumari@essex.ac.uk (M.  Kumari).
ttp://dx.doi.org/10.1016/j.psyneuen.2016.02.021
306-4530/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
positive association between sleep duration and salivary cortisol
on waking. However, many of the studies reviewed reported no sig-
niﬁcant association and sample sizes in most cases were modest.
Only four studies were based on a sample of more than 200 par-
ticipants (Kumari et al., 2009; Schlotz et al., 2004; Vreeburg et al.,
2009; Wust et al., 2000). One of these found evidence of associations
between both short sleep duration, sleep disturbance and a ﬂat-
ter diurnal cortisol secretion slope in a middle-aged occupational
cohort (Kumari et al., 2009). In this study short sleep duration (5 h
or less) was  also associated with an increased cortisol awakening
response (Kumari et al., 2009). Based on laboratory studies, plau-
sible mechanisms by which short sleep duration may alter diurnal
cortisol include the diminution of the feedback mechanism of cor-
tisol regulation (Dahlgren et al., 2009) or minimising the secretion
of corticotropin (Steiger, 2002). As with sleep duration, evidence of
an association between insomnia symptoms and cortisol is equiv-
ocal. Some studies have found no association between measures
of sleep quality or insomnia and salivary cortisol (Dahlgren et al.,
2009; Eek et al., 2012; Hsiao et al., 2013). Although self-reported
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nsomnia symptoms have been found to be associated with both
ower cortisol waking values (Backhaus et al., 2004; Hansen et al.,
012) and shallower slopes in cortisol (Hansen et al., 2012; Kumari
t al., 2009).
An association between sleep and cortisol was conﬁrmed
ecently using actigraphy measured sleep duration and efﬁciency
Castro-Diehl et al., 2015). Castro-Diehl et al. (2015) found both
horter sleep and poor sleep quality to be associated with alter-
tions in diurnal cortisol patterns. However, this study was unable
o consider long-term variability in sleep duration or quality. Much
f the evidence has been cross-sectional, and therefore unable to
etermine the temporal nature of the relationship between sleep
nd cortisol. Thus, a major drawback is the lack of knowledge about
he consequences of sleep deprivation over longer periods of time,
s often occurs in real life. These consequences might be negative;
hronic sleep problems might directly alter properties of neuroen-
ocrine stress systems or disturb the reactivity of these systems
Meerlo et al., 2008; van Cauter et al., 2007). However, it is also
ossible that an individual might adapt to constant exposure to
hort sleep or insomnia symptoms, either as they age or through
uctuating sleep requirements. To fully explore these changes, it is
ecessary to examine both sleep duration and disturbance over a
umber of years, which is only possible using longitudinal data.
Despite evidence in younger age groups (Hatzinger et al., 2014;
iel et al., 2015), to the best of our knowledge there have been no
ongitudinal studies that have examined recurrent short sleep dura-
ion and chronic insomnia symptoms in relation to salivary cortisol
n older adults. Longitudinal data are available in the Whitehall II
tudy and accordingly, our objective in this paper is to address the
ap in the literature and examine the association between poor
uality sleep, characterised by recurrent short sleep duration and
hronic insomnia symptoms, with the diurnal release of cortisol.
elf-reported short sleep duration and insomnia symptoms were
ecorded three times over a 10-year period. Cortisol secretion was
easured at the end of follow-up, using saliva samples taken over a
ingle day to capture the diurnal proﬁle. We  examined the morning
ise in cortisol and the slope in diurnal cortisol separately. The study
as the advantage of being large enough to account for a number of
ovariates associated with both sleep and cortisol in the analyses.
. Method
.1. Participants
The Whitehall II cohort was initially recruited in 1985–1988
rom Civil Service departments based in London (phase 1),
he ﬁnal sample consisted of 10,308 participants aged 35–55
response rate 73%). Follow up screening examinations took place
n 1991–1993 (phase 3), 1997–1999 (phase 5), 2003–2004 (phase
) and 2007–2009 (phase 9) with postal questionnaires being sent
o participants in 1989 (phase 2), 1995 (phase 4), 2001 (phase 6)
nd 2006 (phase 8). We  used exposure data from three phases of
his study (1997–1999, 2003–2004 and 2007–2009) to measure
hronic insomnia symptoms and duration. Cortisol secretion from
007–2009 was used. The number of participants who were eligi-
le for cortisol assessment in phase 9 was 6044 and of those 5106
85%) returned samples. Further details of the Whitehall II Study
an be found elsewhere. Ethical approval for the Whitehall II study
as obtained from the University College London Medical School
ommittee on the Ethics of Human Research..2. Sleep exposures
Sleep duration and insomnia symptoms were self-reported at
997–1999 (phase ﬁve), 2003–2004 (phase 7) and 2007–2009crinology 68 (2016) 91–99
(phase 9). Sleep duration was measured by asking: “How many
hours of sleep do you have on an average week night?”; partic-
ipants were offered ﬁve options 5 h or less, 6 h, 7 h, 8 h or 9 h or
more. Recurrent short sleep was  deﬁned as the number of times,
out of three possible, that short (≤5 h/night) sleep was reported;
Chronic insomnia symptoms were measured using the Jenkins’
sleep problem scale (Jenkins et al., 1988). Participants were asked
how many times during the last month they: (1) “Have trouble
falling asleep,” (2) “Have trouble staying asleep (i.e. waking up far
too early)” (3) “Wake up several times per night” and (4) “Wake
up after usual amount of sleep feeling tired and worn out.” The fol-
lowing response categories were available: Not at all, 1–3 days, 4–7
days, 8–14 days, 15–21 days and 22–31 days. For the analysis this
scale was  summed and then grouped into quartiles. The ﬁrst three
quartiles were grouped together (low insomnia symptoms) and the
fourth quartile was grouped separately (high insomnia symptoms).
Chronic insomnia symptoms were deﬁned as number of times out
of three possible that a high level of insomnia symptoms were
reported.
2.3. Cortisol data collection and outcome
The data collection procedure for the collection of salivary
cortisol at phase 9 in Whitehall II has been reported previ-
ously (Singh-Manoux et al., 2014). Participants who agreed were
asked to take six samples using salivettes over the course of a
normal weekday. They were instructed to take these at the fol-
lowing times: un-rested at waking (sample 1), waking + 30 min
(sample 2), waking + 2.5 h (sample 3), waking +8 h (sample 4),
waking + 12 h (sample 5), and bedtime (sample 6). Participants
were asked to record the time of sample collection in a log-
book and were also required to provide information on their
wake time and stressful events on the day of sampling. The mean
(m), SD (sd) and range (r) for the six sampling times are as fol-
lows: sample 1 (m:07:00, sd:01:03, r:11:31), sample 2 (m:07:31,
sd:01:03, r:11:31), sample 3 (m:09:34, sd:01:04, r:11:01), sam-
ple 4 (m:15:05, sd:01:06, r:12:01), sample 5 (m:19:05, sd:01:14,
r:11:31), sample 6 (m:19:12, sd:08:16, r:15:00). Sensitivity analy-
sis was  conducted which excluded samples which lay more than
2 SD from the mean time of collection. The salivettes and logbook
were then returned via the mail in a prepaid envelope. Salivette
devices were centrifuged at 3000 rpm for 5 min, resulting in a clear
supernatant of low viscosity. Salivary cortisol levels were mea-
sured using a commercial immunoassay with chemiluminescence
detection (CLIA; IBL-Hamburg, Hamburg, Germany). The limit of
detection was  0.44 nmol/l; intra- and inter-assay coefﬁcients of
variance were less than 8%. Any sample greater than 50 nmol/l was
repeated.
Cortisol values for each of the six samples were excluded if
they lay more than 3 SDs from the mean cortisol concentration for
their sample. However, despite this, the distribution was  skewed,
so cortisol data were transformed by natural logarithm. The vari-
able “hours since waking” was  based on the respondents’ recorded
waking time and time of sampling in the log book. Stress on the day
of cortisol sampling was measured using a question from the log-
book that asked whether the participant had experienced a stressful
event and if so how stressful this was. These responses were coded
into binary categories: no/moderately and very/most stressed ever
felt.
2.4. CovariatesSeveral covariates, measured at phase nine (2007–2009), were
also included: age, sex, current or last known employment grade,
smoking status and Body Mass Index (BMI). A binary variable was
also created to capture high alcohol intake, (≥14 units/week for
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alue o
w
s
r
a
c
w
a
1
(
2
d
c
d
e
(
(
s
o
s
a
v
t
d
3
r
u
h
c
w
a
1
i
s
r
aFig. 1. Diurnal cortisol slope by recurrent short sleep (mean predicted v
omen and ≥22 units/week for men). The Short Form-36 health
urvey (SF-36) is a 36 item questionnaire which measures health
elated well-being (Ware et al., 1994). We  used both the physical
nd mental functioning component scores considered to be con-
eptually distinct measures of physical (SF-36: PCS) and mental
ell-being (SF-36: MCS). Self-reported steroid medication (local
nd systemic), sleeping tablets and anti-depressant use in the last
4 days was extracted using British National Formulary codes
BNF).
.5. Analysis
As the cortisol samples are clustered within individuals, the
ata were analysed using multilevel models. Two separate growth
urve models were considered. The ﬁrst analysed the ln(cortisol)
ata from the ﬁrst two samples (at waking and after 30 min) to
xamine the morning rise in cortisol. The second analysed the ﬁrst
waking), third (2 h after waking), fourth (8 h after waking), ﬁfth
12 h after waking), and bedtime samples to examine the diurnal
lope in cortisol. In each of these models, ln(cortisol) was  regressed
n hours since waking and the sleep exposure variables (recurrent
hort sleep and chronic insomnia symptoms), with dummy  vari-
bles for the cortisol samples. Interaction terms between the sleep
ariables and hours since waking were included in the models to
est whether the cortisol proﬁles in the morning or later in the day
iffered between the sleep groups as time increased.
. Results
The initial sample was composed of 5106 respondents who
eturned the saliva samples. Of those 4862 respondents had six
sable cortisol measures and had completed the logbook, and 4763
ad no missing sample times. Of these, 4498 were not taking corti-
osteroid medications and 4172 respondents took their ﬁrst sample
ithin 15 min  of waking without doing any activity ﬁrst. Restricting
nalyses to participants who collected the second sample within
5–45 min  of waking, the third sample within 1–4 h since wak-
ng, the fourth sample within 5–10 h since waking, and the ﬁfth
ample within 10–14 h since waking restricted the sample to 3990
espondents. After eliminating outliers (N = 173) and taking into
ccount missing covariates, the analytical sample included 3125f ln (cortisol) by hours since waking, estimated from model 1, Table 2).
respondents. A Supplementary table comparing key covariates for
those included and those excluded from the sample is available in
the appendix (Table A.1).
Table 1 reports the characteristics of the participants included
in the study at phase 9 by chronic insomnia symptoms and recur-
rent short sleep duration. Overall 87.1% of the sample (N = 2722)
reported no occurrences of short sleep at any of the phases and
2.2% of the sample (N = 69) reported short sleep at every phase,
these participants reported stable patterns of short sleep dura-
tion. Altogether 7.8% (N = 243) of the sample reported only one
occurrence of short sleep; of these 2.6% (N = 81) reported this at
phase one, 2.2% (N = 70) at phase two and 2.9% (N = 92) at the
third phase. Around 2.9% (N = 91) of the sample reported two
occurrences of short sleep duration; of these N = 28 were from
phases ﬁve and seven, N = 21 were from phases ﬁve and nine and
N = 42 were from phases seven and nine. Mean cortisol at each
sample time is consistent across occurrences of chronic insom-
nia symptoms. Participants that report recurrent short sleep are
more likely to be from the lowest employment grades, have higher
BMI  scores and be smokers. Table 2 shows results for the regres-
sion of ln(cortisol) on waking, at 2.5 h, 8 h, 12 h and at bedtime on
recurrent short sleep. Results adjusted for waking time show an
average linear slope for ln(cortisol) of −0.14 in those with no occur-
rences of short sleep; this reﬂects a decline in cortisol across the
day. The squared term for hours since waking is positive (0.003)
indicating that the magnitude of this decline reduces gradually
throughout the day. This is seen in Fig. 1.
Short sleep on three occasions, at phases 5, 7 and 9, is associ-
ated with a lower level of cortisol on waking, compared with never
reporting short sleep. The signiﬁcant interaction terms between the
number of occasions of short sleep and hours since waking indicate
that, as the day progresses, those with short sleep on any occasion,
compared to no short sleep, have a shallower decline in ln(cortisol)
throughout the day. Compared with the decline in ln(cortisol) of
−0.14 per hour in those with no occurrences of short sleep, those
who reported three occurrences of short sleep have a decline of
−0.12 (ˇ = −0.14 + 0.02) per hour. Therefore, in addition to starting
with lower levels of cortisol, they ‘catch-up’ across the day and end
up with higher levels. In Fig. 1, a ﬂatter cortisol slope is visible for
those who reported short sleep on any occasion, especially those
who reported it on three occasions. These effects remain in Model
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Table 1
Characteristics of participants at Whitehall II phase 9 (2007–2009).
N = 3064 Chronic insomnia symptomsa Recurrent short sleep durationb
Mean (SD) or (%) All (N = 3064) No occurrences
(N = 1998)
One occurrence
(N = 524)
Two occurrences
(N = 310)
Three
occurrences
(N = 232)
P value No occurrences
(N = 2672)
One occurrence
(N = 234)
Two occurrences
(N = 90)
Three
occurrences
(N = 68)
P value
Mean Cortisol at:
Waking (nmol/l) 14.8 (7.3) 15.1 (7.4) 14.5 (6.8) 14.6 (6.9) 14.0 (7.6) 0.05c 15.0 (7.3) 14.2 (7.1) 13.2 (7.8) 12.4 (7.6) <0.001c
Waking + 30 min  (nmol/l) 21.3 (10.6) 21.3 (10.7) 21.4 (10.2) 21.3 (10.7) 21.5 (10.1) 0.91c 21.4 (10.5) 20.9 (10.8) 22.2 (11.1) 20.1 (10.1) 0.60c
Waking + 2.5 h (nmol/l) 9.7 (6.0) 9.6 (5.9) 9.8 (5.7) 9.6 (6.1) 9.9 (6.4) 0.89c 9.6 (5.9) 10.0 (5.9) 10.3 (6.6) 10.6 (7.3) 0.38c
Waking + 8 h (nmol/l) 6.0 (3.6) 5.8 (3.3) 5.8 (3.5) 5.8 (3.5) 6.0 (4.0) 0.84c 5.9 (3.5) 6.2 (4.0) 5.8 (3.8) 5.9 (3.6) 0.77c
Waking + 12 (nmol/l) 3.4 (2.8) 3.4 (2.8) 3.4 (2.8) 3.2 (2.5) 3.3 (2.2) 0.71c 3.3 (2.7) 3.8 (3.2) 3.5 (2.2) 2.9 (2.0) 0.03c
Bedtime (nmol/l) 2.5 (2.4) 2.6 (2.4) 2.6 (2.5) 2.5 (2.6) 2.3 (1.8) 0.59c 2.5 (2.2) 3.1 (3.6) 2.9 (3.2) 3.4 (3.4) 0.004c
Waking time 06:58 07:00 06:55 06:51 06:57 0.07d 07:01 06:45 06:41 06:27 <0.001d
High stress 2.45 1.70 2.9 3.2 6.9 <0.001e 2.2 3.0 3.3 8.8 0.005e
Sex (% men) 74.5 78.5 71.6 65.5 58.6 0.001e 76.2 63.7 65.6 55.9 <0.001e
Age (yr) 65.9 65.9 66.2 65.7 66.0 0.78d 65.9 66.3 65.5 66.2 0.69d
Lowest employment grade (%) 7.2 7.1 5.9 8.1 9.9 0.02e 6.1 12.8 12.2 22.1 0.001e
SF-36 MCS  54.3 (7.7) 56.0 (6.0) 53.0 (8.1) 51.0 (9.3) 47.3 (10.7) <0.001d 54.7 (7.3) 52.3 (9.3) 51.5 (10.3) 52.0 (9.3) <0.001d
SF-36 PCS 49.2 (8.3) 50.6 (7.1) 47.8 (9.2) 46.2 (9.8) 45.2 (10.7) <0.001d 49.6 (8.1) 47.7 (9.7) 46.1 (9.8) 45.6 (10.0) <0.001d
Current smoker (%) 6.0 6.3 5.7 5.2 5.2 0.78e 5.9 7.3 4.4 8.8 0.56e
High alcohol intake 14.8 14.4 16.0 14.5 16.0 0.77e 15.1 11.5 16.7 13.2 0.47e
BMI  (kg/m2) 26.5 (4.2) 26.3 (4.1) 26.8 (4.2) 27.2 (4.5) 27.1 (4.8) <0.001d 26.4 (4.2) 27.4 (4.4) 27.1 (4.7) 28.0 (5.0) <0.001d
Sleeping tablets 1.2 0.5 1.7 2.9 4.3 <0.001f 1.0 2.6 4.4 1.5 0.008f
Anti-depressants 5.9 3.6 7.3 11.3 15.5 <0.001f 5.3 12.8 5.6 5.9 <0.001f
Steroid medication 3.4 3.1 2.9 4.2 6.0 0.09f 3.4 2.1 3.3 7.4 0.22f
BMI; body mass index; SF-36 (MCS), Short Form Health Survey mental well-being component scores; SF-36 (PCS), Short Form Health Survey physical component scores.
a Number of times high level of insomnia symptoms reported.
b Number of times short sleep reported.
c Kruskal–Wallis test.
d ANOVA.
e Chi squared test.
f Fisher’s exact test.
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Table  2
Ln(cortisol) on waking and waking plus 2.5, 8, and 12 h and bed time (diurnal slope) on recurrent short sleep and chronic insomnia symptoms.
N = 3,064 Recurrent short sleep duration Chronic insomnia symptoms
Model 1 Model 2 Model 1 Model 2
ˇ (SE) P value ˇ (SE) P value ˇ (SE) P value ˇ (SE) P value
Hours since waking −0.141 (0.048) 0.004 −0.139 (0.048) 0.004 −0.149 (0.048) 0.002 −0.151 (0.048) 0.002
Hours since waking squared 0.005 (0.002) 0.003 0.005 (0.002) 0.003 0.005 (0.002) 0.001 0.005 (0.002) 0.001
Recurrent short sleep (frequency)
No occurrences of short sleep REF REF
One  occurrence −0.029 (0.035) 0.411 −0.017 (0.036) 0.635
Two occurrences −0.108 (0.056) 0.052 −0.094 (0.056) 0.088
Three occurrences −0.190 (0.063) 0.003 −0.163 (0.064) 0.010
Interaction: hrs since waking × short sleep
No  occurrences of short sleep REF REF
One  occurrence × hours since wakinga 0.009 (0.004) 0.015 0.009 (0.004) 0.015
Two occurrences × hours since wakingb 0.014 (0.006) 0.014 0.014 (0.006) 0.014
Three occurrences × hours since wakingc 0.020 (0.006) 0.002 0.020 (0.006) 0.002
Chronic insomnia symptoms (frequency)
No  occurrences of insomnia symptomsd REF REF
One  occurrence 0.003 (0.026) 0.912 0.004 (0.026) 0.884
Two  occurrences −0.015 (0.032) 0.628 −0.020 (0.033) 0.548
Three occurrences −0.052 (0.036) 0.154 −0.060 (0.039) 0.123
Interaction: hrs since waking × insomnia symptoms
No  occurrences of insomnia symptoms REF REF
One  occurrence × hours since wakinge −0.001 (0.003) 0.802 −0.001 (0.003) 0.801
Two  occurrences × hours since wakingf −0.003 (0.003) 0.322 −0.003 (0.003) 0.320
Three occurrences × hours since wakingg 0.002 (0.004) 0.553 0.002 (0.004) 0.552
Model 1: recurrent short sleep (frequency) adjusted for cortisol sample number (dummy variables for whether the cortisol came from ﬁrst/third/fourth/ﬁfth/sixth
sample—estimates of these, compared to the ﬁrst sample are, −0.17, −0.20, −0.66 and −0.98 respectively) + waking time, stress of day of sampling. Model 2: Model 1 + age,
sex,  employment grade, smoking, alcohol intake, SF-36 Short Form Health Survey (physical and mental component scores), BMI  (Body Mass Index), steroids, anti-depressants,
sleeping drugs, +other sleep exposure.
a P = 0.58 for one occurrence of short sleep × hours since waking × sex.
b P = 0.61 for two  occurrences of short sleep × hours since waking × sex.
c P value = 0.86 three occurrences of short sleep × hours since waking × sex.
d Insomnia symptoms: deﬁned as number of times, across three time points, participant was in fourth quartile of reported insomnia symptom.
e P = 0.71 for one occurrence of insomnia symptoms × hours since waking × sex.
f P = 0.96 for two  occurrences of insomnia symptoms × hours since waking × sex.
g P value = 0.44 three occurrences of insomnia symptoms × hours since waking × sex.
Fig. 2. Morning rise in cortisol by recurrent short sleep (mean predicted value of ln (cortisol) by hours since waking, estimated from model 1, Table 3).
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Table  3
Ln(cortisol) on waking and after 30 min  (morning rise) on recurrent short sleep and chronic insomnia symptoms.
N = 3064 Recurrent short sleep duration Chronic insomnia symptoms
Model 1 Model 2 Model 1 Model 2
ˇ (SE) P value ˇ (SE) P value ˇ (SE) P value ˇ (SE) P value
Hours since waking 0.78 (0.18) <0.001 0.75 (0.18) <0.001 0.74 (0.18) <0.001 0.73 (0.18) <0.001
Hours since waking squared −0.77 (0.21) <0.001 −0.77 (0.21) <0.001 −0.76 (0.21) <0.001 −0.76 (0.21) <0.001
Recurrent short sleep (frequency)
No occurrences of short sleep
One occurrence −0.05 (0.04) 0.266 −0.03 (0.05) 0.45
Two occurrences −0.20 (0.07) 0.003 −0.19 (0.07) 0.007
Three occurrences −0.26 (0.08) 0.001 −0.22 (0.08) 0.005
Interaction: hrs since waking × short sleep
No occurrences of short sleep
One occurrence × hours since wakinga −0.00 (0.11) 0.980 −0.03 (0.11) 0.99
Two occurrences × hours since wakingb 0.45 (0.17) 0.008 0.46 (0.17) 0.008
Three occurrences × hours since wakingc 0.35 (0.20) 0.071 0.33 (0.20) 0.08
Chronic insomnia symptoms (frequency)
No  occurrences of insomnia symptomsd REF REF
One  occurrence −0.02 (0.03) 0.485 −0.01 (0.03) 0.668
Two  occurrences −0.03 (0.04) 0.417 −0.01 (0.04) 0.798
Three occurrences −0.13 (0.04) 0.004 −0.10 (0.05) 0.046
Interaction: hrs since waking × insomnia symptoms
No  occurrences of insomnia symptoms REF REF
One  occurrence × hours since wakinge 0.10 (0.08) 0.191 0.10 (0.08) 0.194
Two  occurrences × hours since wakingf 0.02 (0.10) 0.826 0.02 (0.10) 0.833
Three occurrences × hours since wakingg 0.30 (0.11) 0.007 0.30 (0.11) 0.006
Model 1: adjusted for cortisol sample number (dummy  variables for whether the cortisol came from ﬁrst/second sample—estimates of these, compared to the ﬁrst sample
are,  0.14) + waking time, stress of day of sample. Model 2: Model 1 + age, sex, employment grade, smoking, SF-36 Short Form Health Survey (physical and mental component
scores) BMI  (Body Mass Index), steroids, anti-depressants, sleeping drugs + other sleep exposure.
a P = 0.50 for one occurrence of short sleep × hours since waking × sex.
b P = 0.09 for two  occurrences of short sleep × hours since waking × sex.
c P value = 0.25 three occurrences of short sleep × hours since waking × sex.
d Insomnia symptoms: deﬁned as number of times, across three time points, participant was in fourth quartile of reported insomnia symptoms.
e P = 0.64 for one occurrence of insomnia symptoms × hours since waking × sex.
 sex.
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(f P = 0.69 for two occurrences of insomnia symptoms × hours since waking × sex.
g P value = 0.66 three occurrences of insomnia symptoms × hours since waking ×
, after controlling for age, sex, employment grade, smoking, SF-36
PCS & MCS), BMI  and chronic insomnia symptoms. Sensitivity anal-
ses following removal of sample time outliers made no difference
o the results.
We  repeated these analyses using chronic insomnia symptoms.
n contrast to recurrent short sleep, ln(cortisol) was not signiﬁcantly
ssociated with chronic insomnia symptoms and the decline in
ortisol through the day was unaffected.
Table 3 shows the adjusted and unadjusted models of ln(cortisol)
n waking and after 30 min, regressed on exposure to recurrent
hort sleep. There is a signiﬁcant interaction between short sleep
n two occasions and hours since waking. Those who  reported
hort sleep on two or more occasions have low levels of cortisol
hen they wake, compared to those who report no short sleep.
s displayed in Fig. 2, the morning rise was steepest for those who
eported short sleep on two occasions. These results were robust in
odel 2 to additional adjustment for other covariates. Table 3 also
hows the morning rise in cortisol associated with chronic insomnia
ymptoms. Those who reported high insomnia symptoms on three
ccasions have lower levels of cortisol when they wake compared
o those who never reported high insomnia symptoms. There is
lso a signiﬁcant interaction between hours since waking and high
nsomnia symptoms on three occasions. As shown in Fig. 3 this
esults in a steeper rise in morning cortisol among those reporting
igh insomnia symptoms on three occasions, compared to those
ho never report insomnia symptoms. Potential differences by sex
n the results were examined by including a three way interaction
sleep exposure × hours since waking × sex). These were not foundto be signiﬁcant for any of the results. P values for these interactions
are reported in the footnotes to Tables 2 and 3.
4. Discussion
To our knowledge, this is the ﬁrst study to describe the asso-
ciation between sleep problems, measured repeatedly over time,
and cortisol patterns throughout the day. Different associations
between the measures of sleep were observed for the decline in
cortisol across the day (slope) and the morning rise in cortisol on
waking. Our novel ﬁndings indicate that recurrent short sleep but
not chronic insomnia symptoms is associated with ﬂatter slopes
for cortisol across the day. A steeper rise in cortisol on waking was
observed for those who reported three occurrences of high insom-
nia symptoms and recurrent short sleep was also associated with
a steeper rise in cortisol. However, this pattern was inconsistent as
it reached statistical signiﬁcance only for those who reported short
sleep on two, but not three occasions. The associations observed
between recurrent short sleep or high insomnia symptoms and
cortisol were each independent of the other sleep measure. Fur-
thermore, they were independent of a range of covariates including
time of waking on the day of saliva sample collection. Whilst previ-
ous ﬁndings in this area are unclear because of small sample sizes
and a lack of repeat measures, our ﬁndings in a large scale study
with repeat data help clarify the literature (Garde et al., 2012).
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dFig. 3. Morning rise in cortisol by chronic insomnia symptoms (mean predic
.1. Short sleep
Our ﬁnding that recurrent short sleep is associated with
he diurnal slope in cortisol accords with previously described
ross-sectional associations for sleep duration and cortisol (Castro-
iehl et al., 2015; Garde et al., 2012; Kumari et al., 2009). The
act that recurrent short sleep was associated with a ﬂatter diur-
al slope in cortisol, independent of chronic insomnia symptoms,
uggests that it is the shorter sleep duration itself which predicts
 ﬂatter cortisol slope across the day. Waking time has also been
ound to be associated with salivary cortisol (Federenko et al., 2004;
talder et al., 2009) in some previous studies, although due to the
maller samples studied, it was not always possible to separate the
ffects of waking time from sleep duration (Federenko et al., 2004).
n this study, the associations between sleep duration and corti-
ol remained consistent when the time at waking was  taken into
ccount. While it is possible that those who reported short sleep
ight be collecting both their ﬁrst and last samples early in the
orning, this does not explain our observations, since in our sam-
le only 28% of those who reported sleeping for less than 5 h at all
hree time points collected their ﬁrst sample earlier than 7 am and
heir last sample later than midnight.
.2. Insomnia symptoms
Although a cross sectional association has also been found
etween insomnia symptoms and the diurnal slope in cortisol
Castro-Diehl et al., 2015; Hansen et al., 2012; Kumari et al., 2009),
e did not ﬁnd a similar relationship in this study. This could sug-
est that the effect of sleep quality on the cortisol diurnal slope
s only apparent in the case of immediate or short term insom-
ia symptoms. A steeper morning rise in cortisol was  observed
or those who reported high insomnia symptoms on three occa-
ions and for those who  reported short sleep on two  occasions.
ross-sectional research which reported an association between
leep and cortisol after waking found a decrease for those report-
ng sleep disturbance or insomnia (Backhaus et al., 2004; Hansen
t al., 2012) and an increase after restricted or short sleep (Vreeburg
t al., 2009; Wust et al., 2000). However, differences in the mea-
urement of both the exposure and the outcome make it difﬁcult to
raw clear comparisons with previous research. Our ﬁndings maylue of ln (cortisol) by hours since waking, estimated from model 1, Table 3).
suggest a common underlying mechanism of disturbed sleep,
which is responsible for alterations in morning cortisol levels.
However, the association between a morning rise in cortisol and
reporting two occurrences of short sleep was independent of
chronic insomnia symptoms. Therefore, a steeper rise in cortisol
may be associated with reporting ﬂuctuating sleep patterns over a
long time period, either in terms of duration or disturbance.
There are several mechanisms through which restricted or
poor-quality sleep can inﬂuence cortisol secretion. Waye et al.
(2003) suggested that lower levels of morning cortisol may  be due
to increased HPA-axis activation during the night, which would
be applicable for those with poor quality sleep in this study.
Sleep debt has itself been hypothesised as a stressor (McEwen,
2006) and experimental evidence in this area has concluded that
restricting sleep has an impact on the metabolic and endocrine
functions of animals and young healthy volunteers (McEwen, 2006;
Meerlo et al., 2008; Spiegel et al., 1999). It has been proposed that
continued exposure to restricted sleep will have long term conse-
quences for the reactivity of these systems and will increase the
risk of long-term health problems (McEwen, 2006; Spiegel et al.,
1999). McEwen (2006) argued that these long term consequences
of sleep on the systems on the body represent allostatic load, where
the accumulated wear and tear on the body systems of too much
stress has resulted in poor adaptation. Similar arguments have been
presented by others and although the effects of sleep deprivation
on glucocorticoid levels may  be small, if recurrent, these might rep-
resent a signiﬁcant change to the adaption possibilities of a system
(Meerlo et al., 2008).
While the ﬁndings presented here are independent of a wide
range of co-variates, we  cannot discount residual confounding.
Many factors about the relationship between stress and sleep
remain unknown; for example, we were not able to identify
the reasons why  participants reported either short sleep dura-
tion or insomnia symptoms. We  did not control for depression
in our analysis, because of the overlap with poor sleep but we
adjusted our results for SF-36 scores, which would take into
account general physical and mental health functioning in our sam-
ple. We  also conducted sensitivity analyses excluding those who
were currently taking anti-depressants and the results remained
unchanged. Observing this association across three time points
supports the notion that short sleep duration may  precede changes
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n cortisol secretion in early old age, although further research in
his area is needed ﬁrmly to establish the direction of this associa-
ion.
A key strength of this study was that cortisol levels were
ssessed repeatedly across a day by a large cohort of participants
ho appeared to understand and follow the protocol appropri-
tely. However, these measures were only taken over the course
f a single day, which may  make it hard to gauge average corti-
ol production or 24-h exposure. Another strength of this study
s that both of the exposures assessed (recurrent short sleep and
hronic insomnia symptoms) were measured at three time-points.
lthough a limitation is that these exposure measures were self-
eported, assessments in the primary healthcare setting also rely
n self-reports from patients. Observational studies are beginning
o include objectives measures of sleep duration; however these
ere not available in 1995 when these data were ﬁrst collected in
he Whitehall II study. Additionally, these objective measures are
ess sensitive to insomnia symptoms. We  were not able to take sleep
onditions, e.g. sleep apnoea, into account since these are not mea-
ured in our study; however, we did take BMI  into account in our
nalyses. This should partially account for the potential confound-
ng of this association since those diagnosed with sleep apnoea are
ore likely to be obese. Finally the data used in this study are from
n occupational cohort of middle-aged, white-collar civil servants
nd therefore the generalizability of these ﬁndings would need to
e conﬁrmed in further studies.
We conclude that long term sleep problems are associated with
alivary cortisol and that the patterns of these associations vary for
leep duration and disturbance.
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